Drug developer Denali Therapeutics (DNLI.O) said on Friday its and partner Sanofi's (SASY.PA) experimental drug for a fatal neurodegenerative disease failed to slow decline of motor function in a mid-stage study.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,